Skip to main content
Premium Trial:

Request an Annual Quote

Lazard Places 'Buy' Rating on Sequenom Stock

NEW YORK (GenomeWeb News) – Investment firm Lazard Capital today initiated coverage of Sequenom’s stock with a “Buy” rating and a price target of $20.
 
Sequenom’s shares were trading up 3.2 percent at $7.79 in early Friday trading on the Nasdaq.
 
Lazard’s price target is based on the market potential for non-invasive prenatal diagnostic tests being developed by Sequenom. The San Diego-based firm is developing a test for Down syndrome, and Lazard expects Sequenom to present positive data next week on studies of that test.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.